

# World Journal of *Clinical Oncology*

*World J Clin Oncol* 2024 May 24; 15(5): 576-666



**EDITORIAL**

- 576 Pembrolizumab autoimmune related diabetes: Moving forward, keep learning  
*Garcia JA, Alcaraz D, Holgado E, Couñago F*
- 580 Core needle biopsy for thyroid nodules assessment-a new horizon?  
*Dolidze DD, Covantsev S, Chechenin GM, Pichugina NV, Bedina AV, Bumbu A*
- 587 Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon  
*Lino-Silva LS, Martínez-Villavicencio SB, Rivera-Moncada LF*
- 591 Feasibility and limitations of combined treatment for lateral pelvic lymph node metastases in rectal cancer  
*Zheng YZ, Yan FF, Luo LX*
- 594 Navigating breast cancer brain metastasis: Risk factors, prognostic indicators, and treatment perspectives  
*Karthik J, Sehwat A, Kapoor M, Sundriyal D*
- 599 Colorectal cancer: Getting the perspective and context right  
*Lu JD, Tan KY*

**MINIREVIEWS**

- 603 Receptor tyrosine kinase-like orphan receptor 1: A novel antitumor target in gastrointestinal cancers  
*Wu ZL, Wang Y, Jia XY, Wang YG, Wang H*

**ORIGINAL ARTICLE****Retrospective Cohort Study**

- 614 Different types of tumor microvessels in stage I-IIIa squamous cell lung cancer and their clinical significance  
*Senchukova MA, Kalinin EA, Volchenko NN*

**Retrospective Study**

- 635 Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer  
*Ma XT, Ou K, Yang WW, Cao BY, Yang L*

**Observational Study**

- 644 Impact of the economic crisis and drug shortage on Lebanese cancer patients' care  
*Eid D, Jabbour J, Moujaes E, Kourie HR, Safieddine M, Kattan J*

**Basic Study**

- 653** *In silico* prospective analysis of the medicinal plants activity on the CagA oncoprotein from *Helicobacter pylori*  
*Vieira RV, Peiter GC, de Melo FF, Zarpelon-Schutz AC, Teixeira KN*

**LETTER TO THE EDITOR**

- 664** Integrating disulfidptosis-related long noncoding RNAs in colorectal cancer prognosis: A path to precision medicine  
*Zhang SY*

**ABOUT COVER**

Peer Reviewer of *World Journal of Clinical Oncology*, Serghei Covantsev, BSc, MD, Doctor, Research Scientist, General Surgeon, Surgical Oncologist, Plastic Surgeon, Department of Research and Clinical Development & Department of Emergency Surgery №76, Botkin Hospital, Moscow 125284, Russia kovantsev.s.d@gmail.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Oncology* (*WJCO*, *World J Clin Oncol*) is to provide scholars and readers from various fields of oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJCO* mainly publishes articles reporting research results and findings obtained in the field of oncology and covering a wide range of topics including art of oncology, biology of neoplasia, breast cancer, cancer prevention and control, cancer-related complications, diagnosis in oncology, gastrointestinal cancer, genetic testing for cancer, gynecologic cancer, head and neck cancer, hematologic malignancy, lung cancer, melanoma, molecular oncology, neurooncology, palliative and supportive care, pediatric oncology, surgical oncology, translational oncology, and urologic oncology.

**INDEXING/ABSTRACTING**

The *WJCO* is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJCO* as 2.8; IF without journal self cites: 2.8; 5-year IF: 3.0; Journal Citation Indicator: 0.36.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Qing Zhao*; Production Department Director: *Xu Guo*; Cover Editor: *Xu Guo*.

**NAME OF JOURNAL**

*World Journal of Clinical Oncology*

**ISSN**

ISSN 2218-4333 (online)

**LAUNCH DATE**

November 10, 2010

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Hiten RH Patel, Stephen Safe, Jian-Hua Mao, Ken H Young

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2218-4333/editorialboard.htm>

**PUBLICATION DATE**

May 24, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/204>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Integrating disulfidptosis-related long noncoding RNAs in colorectal cancer prognosis: A path to precision medicine

Shi-Yan Zhang

**Specialty type:** Oncology

**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review report's classification**

**Scientific Quality:** Grade C

**Novelty:** Grade C

**Creativity or Innovation:** Grade C

**Scientific Significance:** Grade C

**P-Reviewer:** Nagaya M, Japan

**Received:** February 2, 2024

**Revised:** March 5, 2024

**Accepted:** April 9, 2024

**Published online:** May 24, 2024



**Shi-Yan Zhang**, Department of Clinical Laboratory, Fuding Hospital, Fujian University of Traditional Chinese Medicine, Fuding 355200, Fujian Province, China

**Corresponding author:** Shi-Yan Zhang, MD, Director, Doctor, Department of Clinical Laboratory, Fuding Hospital, Fujian University of Traditional Chinese Medicine, No. 120 South Road of Old City, Fuding 355200, Fujian Province, China. [myebox@139.com](mailto:myebox@139.com)

### Abstract

This commentary explores the burgeoning field of disulfidptosis-related long noncoding RNAs (lncRNAs) in the prognosis and therapeutic targeting of colorectal cancer (CRC). By evaluating recent research, including the pivotal study "Predicting colorectal cancer prognosis based on long noncoding RNAs of disulfidptosis genes" by Wang *et al*, this analysis underscores the critical role of lncRNAs in deciphering the molecular complexities of CRC. Highlighting the innovative methodologies and significant findings, I discuss the implications for patient survival, therapeutic response, and the potential of lncRNAs as biomarkers for precision medicine. The integration of bioinformatics, clinical databases, and molecular biology in these studies offers a promising avenue for advancing CRC treatment strategies and improving patient outcomes.

**Key Words:** Colorectal cancer; Disulfidptosis; Long noncoding RNAs; Prognosis; Precision medicine

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** This commentary emphasizes the novel role of disulfidptosis-related long noncoding RNAs (lncRNAs) in colorectal cancer prognosis. Focusing on the intersection of genetic research and clinical practice, it highlights how the study of lncRNAs can facilitate the development of targeted therapies and prognostic models. The critical evaluation of recent research underscores the potential of lncRNAs as biomarkers and therapeutic targets, marking a significant step towards personalized medicine in colorectal cancer treatment.

**Citation:** Zhang SY. Integrating disulfidptosis-related long noncoding RNAs in colorectal cancer prognosis: A path to precision medicine. *World J Clin Oncol* 2024; 15(5): 664-666

**URL:** <https://www.wjgnet.com/2218-4333/full/v15/i5/664.htm>

**DOI:** <https://dx.doi.org/10.5306/wjco.v15.i5.664>

## TO THE EDITOR

I recently read the insightful study titled "Predicting colorectal cancer prognosis based on long noncoding RNAs of disulfidptosis genes" by Wang *et al*[1] published in *World Journal of Clinical Oncology*. The study pioneers the exploration into the prognostic value of disulfidptosis-related lncRNAs (DRLs) in colorectal cancer (CRC). Through meticulous analysis and innovative approaches, the research uncovers eight significant lncRNAs associated with disulfidptosis, shedding light on their potential as prognostic markers and therapeutic targets.

Key methodologies like leveraging The Cancer Genome Atlas for data collection and the development of a prognostic model through bioinformatics techniques, showcasing the integration of clinical and genetic data for precision medicine. The findings suggest a profound connection between lncRNAs, immune response, and CRC prognosis, offering a novel perspective on cancer treatment strategies. Furthermore, drug sensitivity analysis indicated that Epirubicin, bortezomib, teniposide, and BMS-754807 exhibit the least sensitivity among the assessed immunotherapy drugs, underscoring the necessity for customized therapeutic approaches to augment cancer treatment efficacy.

The relevance of this study is further underscored by related literature, such as the validation of lncRNA prognostic models in CRC, the prognostic significance of disulfidptosis-associated lncRNA signatures, and their implications for the tumor microenvironment and therapeutic options[2-4]. These complementary studies highlight the potential of lncRNAs in understanding CRC's molecular mechanisms and in developing targeted therapies.

The study's findings are pivotal, offering a novel perspective on CRC treatment strategies through DRL utilization. This advancement could revolutionize precision medicine by enabling more personalized and effective treatments. Future research is essential to understand DRLs' impact on CRC progression and treatment response, and their viability as therapeutic targets, potentially leading to innovative treatments that significantly improve patient outcomes[5]. Validating the functions of disulfidptosis-related lncRNAs and immune checkpoints' anti-cancer mechanisms through comprehensive animal and cell studies is imperative.

## FOOTNOTES

**Author contributions:** Zhang SY wrote and edited the manuscript.

**Conflict-of-interest statement:** The author reports no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Shi-Yan Zhang 0000-0003-4305-8213.

**S-Editor:** Gong ZM

**L-Editor:** A

**P-Editor:** Zhao YQ

## REFERENCES

- 1 Wang KL, Chen KD, Tang WW, Chen ZP, Wang YJ, Shi GP, Chen YG. Predicting colorectal cancer prognosis based on long noncoding RNAs of disulfidptosis genes. *World J Clin Oncol* 2024; 15: 89-114 [PMID: 38292658 DOI: 10.5306/wjco.v15.i1.89]
- 2 Wu Y, Xu X. Long non-coding RNA signature in colorectal cancer: research progression and clinical application. *Cancer Cell Int* 2023; 23: 28 [PMID: 36797749 DOI: 10.1186/s12935-023-02867-0]
- 3 Xiao L, Yin W, Chen X, Zhang X, Zhang C, Yu Z, Lü M. A disulfidptosis-related lncRNA index predicting prognosis and the tumor microenvironment in colorectal cancer. *Sci Rep* 2023; 13: 20135 [PMID: 37978247 DOI: 10.1038/s41598-023-47472-3]
- 4 Xue W, Qiu K, Dong B, Guo D, Fu J, Zhu C, Niu Z. Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma. *Cancer Cell Int* 2023; 23: 218 [PMID: 37759294 DOI: 10.1186/s12935-023-03065-8]
- 5 Chi H, Huang J, Yan Y, Jiang C, Zhang S, Chen H, Jiang L, Zhang J, Zhang Q, Yang G, Tian G. Unraveling the role of disulfidptosis-related

LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms. *Front Mol Biosci* 2023; **10**: 1254232 [PMID: 37916187 DOI: 10.3389/fmolb.2023.1254232]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

